SHARE NOW
AVAILABLE ON DEMAND
WATCH NOW | MEET THE PANEL
Access the information from the slides here
Optimizing gene payload begins with plasmid design.
That’s where the Nanoplasmid™ vector platform has shown benefits over traditional plasmids. The small (<500bp) backbone reduces potential plasmid silencing in target cells and tissues compared to plasmids containing up to 1.5–2kb of bacterial regions and junk DNA.
With benefits across applications including transposons, HDR/CRISPR, viral vectors, and mRNA; nanoplasmids are designed to replace antiquated bacterial backbones, while eliminating antibiotic marker that can cause regulatory concerns.
Join us for a discussion on how nanoplasmid benefits may accelerate therapies.
WHAT TO EXPECT
Part 1: The panel will address the unique opportunities associated with using nanoplasmids over traditional plasmids (dependent on application), including:
- AAV application: safety benefits.
- Lentiviral application: significant increase in viral titres and additional safety benefits.
- Cell therapy: reduced cell death which leads to improved performance and longevity.
Part 2: The panel answers audience questions with an interactive Q&A.
MEET THE PANEL
Jim Williams
Chief Scientific Officer, VP R&D
Nature Technology Corporation
Emma Bjorgum
VP, DNA Client Services
Aldevron
Ellen Shafer
Senior Director of Marketing & Communications
Aldevron
Tyler Koziek
Research and Development Scientist
Aldevron
This webinar will be produced in partnership with Aldevron.
